David Dwyer
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Immune Cell Function and Interaction, T-cell and B-cell Immunology, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses
Most-Cited Works
- → Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression(2014)977 cited
- → BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling(2013)80 cited
- → Cutting Edge: Regulation of CD8+ T Cell Effector Population Size(2004)41 cited
- → Synergistic Effect of IL-6 and IL-4 in Driving Fate Revision of Natural Foxp3+ Regulatory T Cells(2010)30 cited
- → Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK(2013)30 cited
- → The immune system provides a strong response to even a low exposure to virus(2006)19 cited
- → Suppression of apoptosis by BRAF inhibitors through off-target inhibition of JNK signaling.(2012)2 cited
- → Congenital Unilateral Renal Aplasia in a Cynomolgus Monkey (Macaca fascicularis) With Investigation Into Potential Pathogenesis(2020)2 cited
- → Abstract A21: microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis.(2014)
- → Author response: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling(2013)